Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fredrick M Wigley

Showing results (1-10 of 148) with videos related to

Pageof 15
Sort By:
Rheumatic Diseases Clinics of North America|March 11, 2008
Systemic sclerosis (scleroderma) is unique among our rheumatic diseases. PrefaceFredrick M Wigley
The New England Journal of Medicine|September 27, 2002
Clinical practice. Raynaud's PhenomenonFredrick M Wigley
Clinical Reviews in Allergy & Immunology|December 11, 2008
Vascular disease in sclerodermaFredrick M Wigley
Rheumatic Diseases Clinics of North America|July 27, 2015
Management of Raynaud Phenomenon and Digital Ulcers in SclerodermaLaura Cappelli, Fredrick M Wigley
Current Opinion in Rheumatology|October 15, 2005
Understanding, assessing and treating Raynaud's phenomenonFrancesco Boin, Fredrick M Wigley
Current Opinion in Rheumatology|November 1, 2002
Targeting mediators of vascular injury in sclerodermaLionel Schachna, Fredrick M Wigley
Current Opinion in Rheumatology|October 6, 2007
Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based reviewSheridan Henness, Fredrick M Wigley
International Journal of Clinical Rheumatology|November 3, 2015
Raynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and managementZsuzsanna H McMahan, Fredrick M Wigley
Rheumatic Diseases Clinics of North America|July 5, 2003
Management of Raynaud's phenomenon and digital ischemic lesions in sclerodermaLaura K Hummers, Fredrick M Wigley
Best Practice & Research. Clinical Rheumatology|February 3, 2020
Raynaud's phenomenonAriane L Herrick, Fredrick M Wigley
Pageof 15

Showing results (1-10 of 148) with videos related to

Sort By:
Pageof 15
Rheumatic Diseases Clinics of North America|March 11, 2008
Systemic sclerosis (scleroderma) is unique among our rheumatic diseases. PrefaceFredrick M Wigley
The New England Journal of Medicine|September 27, 2002
Clinical practice. Raynaud's PhenomenonFredrick M Wigley
Clinical Reviews in Allergy & Immunology|December 11, 2008
Vascular disease in sclerodermaFredrick M Wigley
Rheumatic Diseases Clinics of North America|July 27, 2015
Management of Raynaud Phenomenon and Digital Ulcers in SclerodermaLaura Cappelli, Fredrick M Wigley
Current Opinion in Rheumatology|October 15, 2005
Understanding, assessing and treating Raynaud's phenomenonFrancesco Boin, Fredrick M Wigley
Current Opinion in Rheumatology|November 1, 2002
Targeting mediators of vascular injury in sclerodermaLionel Schachna, Fredrick M Wigley
Current Opinion in Rheumatology|October 6, 2007
Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based reviewSheridan Henness, Fredrick M Wigley
International Journal of Clinical Rheumatology|November 3, 2015
Raynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and managementZsuzsanna H McMahan, Fredrick M Wigley
Rheumatic Diseases Clinics of North America|July 5, 2003
Management of Raynaud's phenomenon and digital ischemic lesions in sclerodermaLaura K Hummers, Fredrick M Wigley
Best Practice & Research. Clinical Rheumatology|February 3, 2020
Raynaud's phenomenonAriane L Herrick, Fredrick M Wigley
Pageof 15